Zim Laboratories Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ix8tm3szxz0k5u077wz76cef.pdf

Key Takeaways


EU-GMP Suspension & Remediation

Anwar Daud: "We realize that many of these -- the question marks that are raised by different authorities are basically a result of overreliance on manual documentation. The company has instituted a switch..."

Revenue Recovery & H2 Dependence

Anwar Daud: "So there was some effect because of the audit because we needed to assess and previously consider whether the observation that has been noted given by the auditors, whether they would actually attract some -- any quality-related issues for all the offerings that we make."

Site Transfers & Alternate Supply


Margins & Financials


FY27 Aspiration & Long-Term Levers

Anwar Daud: "During this audit, there was also audit of the products, other data that is relevant to the product and the manufacturing processes. And it was quite an in-depth audit because of how the auditor was looking at the systems existing in the company, but they did not find any observation or any significant observation on the product, the dossier, the product, the information that goes into the product dossier and the quality of the information..."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenueBroadly in line with FY25 revenuesFY26 full year
FY26 EBITDA marginRemain constant at current levels through Q3 and Q4FY26 H2
Tamsulosin + Dutasteride commercial suppliesFrom alternate TGA-approved siteWithin next 6 months
Dimethyl Fumarate salesFrom CMO partner in ROW and emerging marketsH2 FY26
Nutraceutical deferred ordersDomestic institutional orders to materializeQ3 and Q4 FY26
NIP/OTF order position moderationDecline to moderate as H2 orders deliverNext 2 quarters
EU-GMP NIP product salesResume from suspended facilityQ1 or Q2 FY27
EU-GMP reinspection readinessCompany ready from its end per consultant timelineQ4 FY26
FY27 growth and margin aspiration20-25% revenue growth, 14-15% EBITDA marginFY27, subject to conditions

Key Metrics

MetricQ2 FY26
Total operating income₹88.7 cr, +23.6% QoQ
EBITDA₹7.8 cr, margin 8.8% vs 7.9% in Q1 FY26
PATLoss of ₹0.4 cr, vs loss of ₹1.9 cr in Q1 FY26
Pharma segment revenue₹73.2 cr, 83% of total revenue, +30.7% QoQ
Nutra segment revenue₹15.5 cr, 17% of total revenue; decline due to deferred domestic institutional orders
Export revenue₹72.8 cr, +21% QoQ
Domestic revenue₹12.7 cr, broadly stable QoQ
NIP and OTF portfolio revenue₹8.1 cr
Licensing income₹2.9 cr
R&D investment₹7.6 cr
Gross contribution margin51% in H1 FY26, vs 49.3% in H1 FY25
FY26 revenue guidanceBroadly in line with FY25 revenues
Inventory days109 days, vs 83 days in prior period; absolute increase of ~₹10 cr
Debtor days78 to 90 days, normal range
Total debt~₹120 cr, comprising term loan of ~₹66 cr and cash credit of ~₹51 cr
CAPA-related capex~₹5 cr, approved by Board